Candidiasis is a fungal infection affecting men and women, of all age groups. Approximately 46,000 cases of healthcare-associated invasive candidiasis occur each year in the US. The major drug classes for treatment include azoles, polyenes and echinocandins. The candidiasis therapeutics market is highly fragmented with many Generics. Owing to the widespread nature of the disease, the market is highly dynamic as recurrent infections, limitations of safe and efficacious antifungals and the lack of reliable preventative approaches.
Global Candidiasis Therapeutics - Market Dynamics
The report details several factors driving and restraining the market, some of which are discussed below.
Increase in the susceptible immune compromised patient pool
Growing awareness of candidiasis infection
Unmet need for safe products in the market
Availability of alternative treatments
Narrow pipeline molecules
Competition from herbal medicines and alternate therapies
The global candidiasis therapeutics market has been segmented by route of administration (injection, ointment, oral), drug type (polyene, azole, echinocandin, and others), anatomy type (oral, vulvovaginal, cutaneous, invasive, systemic) and distribution channel (hospitals, clinics, retail pharmacies, drug stores). The market has been geographically segmented into North America, Europe, Asia-Pacific, and Rest of the World.
Major Companies in the Sector Include:
This Report Offers:
Market definition, along with identification of key drivers and restraints for the market.
Market analysis with region-specific assessments and competition analysis on a global and regional scale.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.
Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.
A comprehensive list of key market players, along with the analysis of their current strategic interests and key financial information.
An ideal source material for industry consultants, manufacturers and other interested and allied parties to gain critical insight into the factors driving and restraining the market, in addition to opportunities, offered.
1.1 Study Deliveratives
1.2 Market Definition
1.3 Sizing Units
1.4 Base Currency
1.5 Review and Forecast Period Years
1.6 General Study Assumptions
1.7 Report Description
2. RESEARCH METHODOLOGY
2.2 Analysis Methodology
2.3 Study Timeline
2.4 Study Phases
2.4.1 Secondary Research
2.4.2 Discussion Guide
2.4.3 Market Engineering & Econometric Model
2.4.4 Expert Validation
3. EXECUTIVE SUMMARY
4. KEY INFERENCES
5. MARKET OVERVIEW AND INDUSTRY TRENDS
5.1 Current Market Scenario
5.2 Market Overview
5.3 Porters Five Force Analysis
5.3.1 Bargaining Power Of Suppliers
5.3.2 Bargaining Power Of Buyers
5.3.3 Degree Of Competition
5.3.4 Threat Of Substitution
5.3.5 Threat Of New Entrants
6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)
6.1 Market Drivers
6.1.1 Increase in The Susceptible Immune Compromised Patient Pool
6.1.2 Growing Awareness for Candidiasis Infection
6.1.3 Unmet Need for Safe Products in The Market
6.2 Market Restraints
6.2.1 Availability of Alternative Treatments
6.2.2 Narrow Pipeline Molecules
6.2.3 Competition from Herbal Medicines and Alternate Therapies
6.3 Market Opportunities
6.4 Key Challenges
7. Global Candidiasis Therapeutics Market - Segmentation
7.1 BY ROUTE OF ADMINISTRATION
7.2 BY DRUG TYPE
7.3 BY ANATOMY TYPE
7.3.1 Oral Candidiasis
7.3.2 Vulvovaginal Candidiasis
7.3.3 Cutaneous Candidiasis
7.3.4 Invasive Candidiasis
7.3.5 Systemic Candidiasis
7.4 BY DISTRIBUTION CHANNEL
7.4.3 Retail Pharmacies
7.4.4 Drug Stores
8. Global Candidiasis Therapeutics Market - Regional Shares and Forecast
8.1 North America
8.1.1 United States
8.2.5 Spain & Portugal
8.2.8 Rest of Europe
8.3.4 Australia & New Zealand
8.3.5 South Korea
8.3.6 Rest of Asia-Pacific
8.4 The Middle East and Africa
8.4.2 South Africa
8.4.3 Rest of the Middle East and Africa
8.5 Latin America
8.5.3 Rest of Latin America
9. Competitive Landscape
9.1 Merger and Acquisition Analysis
9.2 New Product Launches
9.3 Agreements, Collaborations & Partnerships
10. Company Profiles
10.1 Basilea Pharmaceuticals
10.3 Ferrer Internacional
10.4 Pacgen Biopharmaceuticals
10.5 NovaDigm Therapeutics
10.6 Pevion Biotech
10.7 Amplyx Pharmaceuticals, Inc.
10.8 Biomar Microbial Technologies
10.9 Cidara Therapeutics, Inc.
10.10 Novabiotics Limited
11. Analyst Outlook for Investment Opportunities
12. Future Outlook of the Market